Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:32 AM
Ignite Modification Date:
2025-12-25 @ 3:32 AM
NCT ID:
NCT01046305
Eligibility Criteria:
Inclusion Criteria:
1. 18 years of age or older (Patient and family caregiver only)
2. Ability to speak and read English (All participants)
3. Live in the United States (Patient Phase 3 only)
4. Diagnosis of Philadelphia chromosome positive CML confirmed by pathological and cytogenetic analysis (Patient only)
5. Being followed at M.D. Anderson Cancer Center (Patient only)
6. Consent to participate (All participants)
7. Treatment for CML for at least 1 year (Patient Phase 2 only)
8. Family caregiver also willing to receive packet for expert panel participation (Patient Phase 2 only)
9. Physician or nurse with at least 5 years experience caring for patients with CML (Professional expert only)
10. At least one publication in the last 5 years dealing with CML (Physician professional expert only)
11. Identification as a family caregiver by a patient with CML (Family caregiver only)
12. Patient also willing to receive packet for expert panel participation (Family caregiver only)
Exclusion Criteria:
1. Medical condition or impaired performance status that would preclude participation in the study (Patient only)
2. Diagnosis of active psychosis or severe cognitive impairment as determined by primary physician (Patient only)
3. Active treatment (systemic drug therapy or radiation therapy) for a second malignancy (Patient only Phase 3)
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01046305
Study Brief:
Protocol Section:
NCT01046305